Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
53.42
+0.65 (+1.23%)
Streaming Delayed Price
Updated: 3:36 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
34
35
Next >
FDA Approves Genentech’s Evrysdi (risdiplam) for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)
May 31, 2022
From
Genentech
Via
Business Wire
New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma
May 26, 2022
From
Genentech
Via
Business Wire
One-Trick Pony Boan Biotech Files for Hong Kong IPO Into Tough Market
↗
May 24, 2022
Key Takeaways: Boan Biotechnology sells only one product so far and is facing stiff competition from other similar drugs Luye Pharma bought Boan in 2020 and is taking it public...
Via
Benzinga
Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare
May 24, 2022
From
Genentech
Via
Business Wire
Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
↗
May 23, 2022
Via
Benzinga
Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients
↗
May 17, 2022
Via
Benzinga
Current Report: Roche Holding
↗
May 16, 2022
Roche’s price per share was $39.75 as of Friday's market close. One year ago its price was $42.20.
Via
Talk Markets
The OTC Markets' Most Active Securities Welcomes New Names And Experiences A Reshuffle In April
↗
May 13, 2022
Photo by Becca on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. First-quarter 2022 market...
Via
Benzinga
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
↗
May 11, 2022
Roche isn't the only company working on an anti-TIGIT molecule.
Via
Investor's Business Daily
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
↗
May 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer
↗
May 11, 2022
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung...
Via
Benzinga
Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
May 11, 2022
From
Genentech
Via
Business Wire
Market Selloff
↗
May 10, 2022
In a U.S. market selloff, the strong performance of mostly foreign issues was impressive.
Via
Talk Markets
Roche Releases More Evrysdi Data For Very Young Infants With SMA
↗
April 29, 2022
Via
Benzinga
New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
April 29, 2022
From
Genentech
Via
Business Wire
Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook
↗
April 26, 2022
Via
Benzinga
Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials
↗
April 25, 2022
The development of Roche Holdings AG's (OTC: RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine.
Via
Benzinga
COVID-19 Tests Boost Roche's Q1 Sales, Reaffirms FY22 Outlook
↗
April 25, 2022
Via
Benzinga
EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs
↗
April 22, 2022
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
↗
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
↗
April 20, 2022
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was...
Via
Benzinga
4 Undervalued Biotech Stocks to Add to Your Buy List
↗
April 20, 2022
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.
Via
InvestorPlace
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers
↗
April 16, 2022
Let’s pause to consider earlier attempts at hostile takeovers by well-respected and well-financed entities and individuals that — to ransack some Musk-worthy clichés — took off like a rocket ship but...
Via
Talk Markets
Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers
↗
April 15, 2022
As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover.
Via
Benzinga
FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy
↗
April 14, 2022
Via
Benzinga
Volume Springs Back Into The OTC Markets In March – Take A Look At Some Of The Top Movers
↗
April 14, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Trading volume appears to be moving back to OTC Markets...
Via
Benzinga
Read Why Pliant Therapeutics Shares Are Soaring Today
↗
April 13, 2022
Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need.
Via
Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
↗
April 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal
Via
Benzinga
Healthcare Stocks Lead the Way Up as the Market Fades
↗
April 11, 2022
With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions.
Via
Talk Markets
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines
↗
April 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
